share_log

金斯瑞生物科技：海外監管公告: 傳奇生物科技股份有限公司公佈CARVYKTI申辦方及FDA簡報文件

GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH CORPORATION RELEASES SPONSOR AND FDA BRIEFING BOOKS FOR CARVYKTI

Hong Kong Stock Exchange ·  Mar 13 09:34
Summary by Moomoo AI
金斯瑞生物科技股份有限公司（「金斯瑞生物科技」）宣布其非全資附屬公司傳奇生物科技股份有限公司（「傳奇生物」）已於2024年3月13日向美國證券交易委員會提交6-K表格，並在3月15日的美國食品藥品管理局（FDA）腫瘤藥物諮詢委員會會議前公佈了關於CARVYKTI®（ciltacabtagene autoleucel; cilta-cel）的申辦方簡報文件。該文件包含CARTITUDE-4 3期試驗的長期生存情況資料，FDA的簡報文件也同時公佈。金斯瑞生物科技提醒股東及潛在投資者注意投資風險，並於買賣公司證券時審慎行事。
金斯瑞生物科技股份有限公司（「金斯瑞生物科技」）宣布其非全資附屬公司傳奇生物科技股份有限公司（「傳奇生物」）已於2024年3月13日向美國證券交易委員會提交6-K表格，並在3月15日的美國食品藥品管理局（FDA）腫瘤藥物諮詢委員會會議前公佈了關於CARVYKTI®（ciltacabtagene autoleucel; cilta-cel）的申辦方簡報文件。該文件包含CARTITUDE-4 3期試驗的長期生存情況資料，FDA的簡報文件也同時公佈。金斯瑞生物科技提醒股東及潛在投資者注意投資風險，並於買賣公司證券時審慎行事。
Kingsway Biotechnology Co., Ltd. (“Kingsley Biotechnology”) Announces Its Non-Wholly-Owned Subsidiary Legendary Biotechnology Co., Ltd. (“Legendary Biotech”) has filed Form 6-K with the U.S. Securities and Exchange Commission on March 15, 2024 with the U.S. Food and Drug Administration on March 15 (FDA) Announces Presentation Paper for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) prior to the meeting of the (FDA) Advisory Committee on Oncology. THE DOCUMENT CONTAINS LONG-TERM SURVIVAL DATA FOR THE CARTITUDE-4 PHASE 3 TRIAL, WHICH WAS ALSO RELEASED BY THE FDA IN A PRESENTATION DOCUMENT. Kingsway Biotechnology reminds shareholders and potential investors to be aware of investment risks and to exercise caution when buying and selling company securities.
Kingsway Biotechnology Co., Ltd. (“Kingsley Biotechnology”) Announces Its Non-Wholly-Owned Subsidiary Legendary Biotechnology Co., Ltd. (“Legendary Biotech”) has filed Form 6-K with the U.S. Securities and Exchange Commission on March 15, 2024 with the U.S. Food and Drug Administration on March 15 (FDA) Announces Presentation Paper for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) prior to the meeting of the (FDA) Advisory Committee on Oncology. THE DOCUMENT CONTAINS LONG-TERM SURVIVAL DATA FOR THE CARTITUDE-4 PHASE 3 TRIAL, WHICH WAS ALSO RELEASED BY THE FDA IN A PRESENTATION DOCUMENT. Kingsway Biotechnology reminds shareholders and potential investors to be aware of investment risks and to exercise caution when buying and selling company securities.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more